User-agent: Twitterbot/1.0
Allow: /programs/cme/test-accreditation-services-omn/10565
Allow: /meeting-reports/new-paradigms-in-the-prevention-of-ascvd-the-role-of-epa-and-triglycerides/the-benefits-of-icosapent-ethyl-in-addressing-residual-risk-what-is-the-evidence/17698
Allow: /topics/inflammation/first-approval-of-inflammation-inhibitor-in-cvd-by-fda/17719
Allow: /cme/heart-failure/qa-test-accreditation-event-pace/24354
Allow: /test-aws/test-aws/qa-test-infograph-ed-program/27133
Allow: /programs/cme/echo-essentials-hcm-heartbeat-diagnosis-and-treatment/29481
Allow: /programs/cme/aufschlusseln-von-juckreiz-bei-ckd-vom-verdacht-auf-ckd-ap-zur-losung/48697
Allow: /programs/cme/ckd-ap-unter-der-oberflache/48698
Allow: /programs/cme/ckd-ap-quantifizieren-tools-fur-eine-bessere-versorgung/48699
Allow: /programs/cme/ckd-ap-oder-etwas-anderes-aufschlusseln-der-diagnose/48700
Allow: /programs/cme/behandlungs-toolkit-fur-ckd-ap/48701
Allow: /programs/cme/verbesserung-der-behandlung-bei-ckd-ap-neue-grenzen/48702
Allow: /programs/cme/versteckt-sich-ckd-ap-in-ihrer-dialyseeinrichtung/48703
Allow: /programs/cme/kappa-opioid-einstellung-einblicke-in-real-world-evidenz/48704
Allow: /programs/cme/verbessern-von-schlaf-und-psychischer-gesundheit-bei-patienten-mit-ckd-ap/48705
Allow: /programs/cme/die-verbindung-zwischen-patient-und-arzt-im-umgang-von-ckd-ap/48706
Allow: /programs/cme/decodificare-il-prurito-nella-ckd-dal-sospetto-di-ckd-ap-alla-soluzione/48751
Allow: /programs/cme/decrypter-les-demangeaisons-dans-la-mrc-de-la-suspicion-de-pa-mrc-a-la-solution/48817
Allow: /programs/cme/decodificar-el-prurito-en-la-erc-de-la-sospecha-de-pa-erc-a-la-solucion/48858
Allow: /programs/cme/pa-erc-mas-alla-de-la-superficie/48859
Allow: /programs/cme/cuantificar-el-pa-erc-herramientas-para-una-mejor-atencion/48860
Allow: /programs/cme/pa-erc-o-algo-mas-como-decodificar-el-diagnostico/48861
Allow: /programs/cme/conjunto-de-herramientas-para-el-tratamiento-del-pa-erc/48862
Allow: /programs/cme/como-elevar-la-atencion-medica-del-pa-erc-nueva-frontera/48863
Allow: /programs/cme/el-pa-erc-se-oculta-en-su-centro-de-dialisis/48864
Allow: /programs/cme/contextos-de-opioides-kappa-datos-de-la-vida-real/48865
Allow: /programs/cme/como-mejorar-el-sueno-y-la-salud-mental-en-pacientes-con-pa-erc/48866
Allow: /programs/cme/the-patient-clinician-connection-in-managing-ckd-ap/48867
Allow: /programs/cme/des-donnees-aux-debats-perspectives-mondiales-sur-la-prise-en-charge-du-csm-hrher2/51023
Allow: /programs/cme/besoins-non-satisfaits-avec-lhormonotherapie-repenser-la-feuille-de-route-du-traitement-du-csm-hrher2/51024
Allow: /programs/cme/analyse-des-criteres-de-reference-donnees-pivots-sur-les-inhibiteurs-des-cdk46-de-premiere-ligne/51025
Allow: /programs/cme/securite-des-inhibiteurs-des-cdk46-anticipation-prevention-et-gestion-des-evenements-indesirables/51026
Allow: /programs/cme/au-dela-du-fulvestrant-les-serd-oraux-redefinissent-le-ciblage-des-recepteurs-hormonaux/51027
Allow: /programs/cme/lavenir-des-serd-oraux-strategies-de-combinaison/51028
Allow: /programs/cme/doublet-ou-triplet-debats-autour-dun-cas-sur-les-choix-de-premiere-ligne-pour-un-csm-hrher2/51029
Allow: /programs/cme/a-la-croisee-des-chemins-debat-autour-dun-cas-sur-la-selection-des-serd/51030
Allow: /programs/cme/gros-plan-sur-leurope-adapter-les-donnees-probantes/51031
Allow: /programs/cme/gros-plan-sur-lamerique-latine-combler-les-lacunes/51032
Allow: /programs/cme/gros-plan-sur-lasie-pacifique-la-pratique-au-dela-des-frontieres/51033
Allow: /programs/cme/von-daten-zur-diskussion-allgemeine-perspektiven-fur-die-behandlung-von-hrher2-mbc/51052
Allow: /programs/cme/hrher2-mbc/51053
Allow: /programs/cme/nicht-erfullte-bedurfnisse-in-der-endrokrinen-therapie-uberdenken-der-behandlungsstrategie-fur-hrher2-mbc/51054
Allow: /programs/cme/aufschlusselung-der-benchmarks-entscheidende-daten-zu-cdk46-inhibitoren-in-der-erstlinientherapie/51055
Allow: /programs/cme/sicherheit-von-cdk46-inhibitoren-antizipation-pravention-und-management-von-nebenwirkungen/51056
Allow: /programs/cme/uber-fulvestrant-hinaus-orale-serds-definieren-er-targeting-neu/51057
Allow: /programs/cme/die-zukunft-oraler-serds-kombinationsstrategien/51058
Allow: /programs/cme/doppel-oder-dreifachtherapie-eine-fallbasierte-diskussion-zu-erstlinientherapien-fur-hrher2-mbc/51059
Allow: /programs/cme/neubewertung-der-darreichungsformen-eine-fallbasierte-diskussion-zur-serd-auswahl/51060
Allow: /programs/cme/europa-im-fokus-anpassung-der-evidenz/51061
Allow: /programs/cme/lateinamerika-im-fokus-schlieen-der-versorgungslucke/51062
Allow: /programs/cme/der-asien-pazifik-raum-im-fokus-grenzuberschreitende-praxis/51063
Allow: /programs/cme/hrher2-mbc/51068
Allow: /programs/cme/cdk46/51069
Allow: /programs/cme/cdk46/51070
Allow: /programs/cme/er-serd/51071
Allow: /programs/cme/serd/51072
Allow: /programs/cme/hrher2-mbc/51073
Allow: /programs/cme/serd/51074
Allow: /programs/cme/HRHER2mBC/51075
Allow: /programs/cme/HRHER2mBC/51076
Allow: /programs/cme/HRHER2mBC/51077
Allow: /programs/cme/dos-dados-ao-debate-perspetivas-globais-sobre-o-tratamento-do-cancro-da-mama-metastatico-hrher2/51493
Allow: /programs/cme/necessidades-nao-atendidas-na-terapia-endocrina-repensando-o-roteiro-de-tratamento-do-cmm-hrher2/51494
Allow: /programs/cme/analisar-os-parametros-de-referencia-dados-fundamentais-sobre-os-inibidores-cdk46-de-primeira-linha/51495
Allow: /programs/cme/seguranca-dos-inibidores-cdk46-antecipacao-prevencao-e-gestao-de-eventos-adversos/51496
Allow: /programs/cme/alem-do-fulvestrant-serd-orais-redefinindo-o-alvo-er/51497
Allow: /programs/cme/o-futuro-dos-serd-orais-estrategias-combinadas/51498
Allow: /programs/cme/dupla-ou-tripla-um-debate-baseado-em-casos-sobre-opcoes-de-primeira-linha-para-cmm-hrher2/51499
Allow: /programs/cme/rotas-reconsideradas-um-debate-baseado-em-casos-na-selecao-serd/51500
Allow: /programs/cme/em-destaque-na-europa-adaptando-as-evidencias/51501
Allow: /programs/cme/destaque-para-a-america-latina-fechar-a-lacuna/51502
Allow: /programs/cme/destaque-para-a-asia-pacifico-pratica-alem-das-fronteiras/51503
Allow: /programs/cme/de-los-datos-al-debate-perspectivas-globales-sobre-la-atencion-del-cmm-hrher2/54097
Allow: /programs/cme/necesidades-insatisfechas-en-el-tratamiento-endocrino-reformulando-la-hoja-de-ruta-del-tratamiento-del-cmm-hrher2/54106
Allow: /programs/cme/desglose-de-los-puntos-de-referencia-datos-fundamentales-sobre-inhibidores-de-cdk46-de-primera-linea/54107
Allow: /programs/cme/seguridad-de-inhibidores-de-cdk46-anticipacion-prevencion-y-control-de-eventos-adversos/54108
Allow: /programs/cme/mas-alla-del-fulvestrant-los-serd-orales-redefinen-el-objetivo-de-los-re/54109
Allow: /programs/cme/el-futuro-de-los-serd-orales-estrategias-de-combinacion/54110
Allow: /programs/cme/tratamiento-doble-o-triple-un-debate-basado-en-casos-sobre-las-opciones-de-primera-linea-para-el-cmm-hrher2/54111
Allow: /programs/cme/reconsideracion-de-las-rutas-un-debate-basado-en-casos-sobre-la-seleccion-de-serd/54112
Allow: /programs/cme/enfoque-en-europa-adaptacion-de-la-evidencia/54113
Allow: /programs/cme/enfoque-en-latinoamerica-cerrando-la-brecha/54114
Allow: /programs/cme/enfoque-en-asia-pacifico-practicas-mas-alla-de-las-fronteras/54115
Allow: /programs/cme/hrher2-mbc/54163
Allow: /programs/cme/hrher2-mbc/54164
Allow: /programs/cme/cdk46/54165
Allow: /programs/cme/cdk46/54166
Allow: /programs/cme/serd-er/54167
Allow: /programs/cme/serd/54168
Allow: /programs/cme/hrher2-mbc/54169
Allow: /programs/cme/serd/54170
Allow: /programs/cme/ESMO/54171
Allow: /programs/cme/ESMO/54172
Allow: /programs/cme/ESMOHRHER2mBC/54173
Allow: /live-events/qa-in-person-live-event-parent-2-child-2/56552
Sitemap: https://pace-cme.org/sitemap.xml
User-agent: *
Disallow: /accounts/reset*
Disallow: /accounts/password_reset*
Disallow: /playlist/top
Disallow: /profiles
Disallow: /profiles/peers/in-common*
Allow: /profiles/*/*/biography/
Disallow: /messages/send_to*
Disallow: /segment/*/
Disallow: /programs/cme/test-accreditation-services-omn/10565
Disallow: /meeting-reports/new-paradigms-in-the-prevention-of-ascvd-the-role-of-epa-and-triglycerides/the-benefits-of-icosapent-ethyl-in-addressing-residual-risk-what-is-the-evidence/17698
Disallow: /topics/inflammation/first-approval-of-inflammation-inhibitor-in-cvd-by-fda/17719
Disallow: /cme/heart-failure/qa-test-accreditation-event-pace/24354
Disallow: /test-aws/test-aws/qa-test-infograph-ed-program/27133
Disallow: /programs/cme/echo-essentials-hcm-heartbeat-diagnosis-and-treatment/29481
Disallow: /programs/cme/crossing-boundaries-cetp-inhibitors-and-the-next-frontier-in-lipid-control/33025
Disallow: /programs/cme/new-insights-in-the-management-of-hcm-exploring-the-clinical-spectrum/33026
Disallow: /programs/cme/aufschlusseln-von-juckreiz-bei-ckd-vom-verdacht-auf-ckd-ap-zur-losung/48697
Disallow: /programs/cme/ckd-ap-unter-der-oberflache/48698
Disallow: /programs/cme/ckd-ap-quantifizieren-tools-fur-eine-bessere-versorgung/48699
Disallow: /programs/cme/ckd-ap-oder-etwas-anderes-aufschlusseln-der-diagnose/48700
Disallow: /programs/cme/behandlungs-toolkit-fur-ckd-ap/48701
Disallow: /programs/cme/verbesserung-der-behandlung-bei-ckd-ap-neue-grenzen/48702
Disallow: /programs/cme/versteckt-sich-ckd-ap-in-ihrer-dialyseeinrichtung/48703
Disallow: /programs/cme/kappa-opioid-einstellung-einblicke-in-real-world-evidenz/48704
Disallow: /programs/cme/verbessern-von-schlaf-und-psychischer-gesundheit-bei-patienten-mit-ckd-ap/48705
Disallow: /programs/cme/die-verbindung-zwischen-patient-und-arzt-im-umgang-von-ckd-ap/48706
Disallow: /programs/cme/decodificare-il-prurito-nella-ckd-dal-sospetto-di-ckd-ap-alla-soluzione/48751
Disallow: /programs/cme/ckd-ap-oltre-la-superficie/48752
Disallow: /programs/cme/quantificare-il-ckd-ap-strumenti-per-una-cura-migliore/48753
Disallow: /programs/cme/ckd-ap-o-altro-decodificare-la-diagnosi/48754
Disallow: /programs/cme/kit-di-strumenti-terapeutici-per-il-ckd-ap/48755
Disallow: /programs/cme/migliorare-lassistenza-per-il-ckd-ap-nuova-frontiera/48756
Disallow: /programs/cme/nel-tuo-centro-dialisi-il-ckd-ap-rimane-in-ombra/48757
Disallow: /programs/cme/impostazioni-oppioidi-kappa-approfondimenti-sulle-prove-concrete-rwe/48758
Disallow: /programs/cme/migliorare-il-sonno-e-la-salute-mentale-nei-pazienti-con-ckd-ap/48759
Disallow: /programs/cme/il-rapporto-paziente-medico-nella-gestione-del-ckd-ap/48760
Disallow: /programs/cme/decrypter-les-demangeaisons-dans-la-mrc-de-la-suspicion-de-pa-mrc-a-la-solution/48817
Disallow: /programs/cme/pa-mrc-au-dela-de-la-surface/48818
Disallow: /programs/cme/quantification-du-pa-mrc-des-outils-pour-ameliorer-les-soins/48819
Disallow: /programs/cme/pa-mrc-ou-autre-chose-decoder-le-diagnostic/48820
Disallow: /programs/cme/boite-a-outils-du-traitement-du-pa-mrc/48821
Disallow: /programs/cme/ameliorer-les-soins-du-pa-mrc-de-nouvelles-frontieres/48822
Disallow: /programs/cme/le-pa-mrc-se-cache-t-il-dans-votre-centre-de-dialyse/48823
Disallow: /programs/cme/contextes-des-recepteurs-opioides-kappa-perspectives-issues-des-donnees-du-monde-reel/48824
Disallow: /programs/cme/ameliorer-le-sommeil-et-la-sante-mentale-des-patients-atteints-de-pa-mrc/48825
Disallow: /programs/cme/la-relation-patient-clinicien-dans-la-prise-en-charge-du-pa-mrc/48826
Disallow: /programs/cme/decodificar-el-prurito-en-la-erc-de-la-sospecha-de-pa-erc-a-la-solucion/48858
Disallow: /programs/cme/pa-erc-mas-alla-de-la-superficie/48859
Disallow: /programs/cme/cuantificar-el-pa-erc-herramientas-para-una-mejor-atencion/48860
Disallow: /programs/cme/pa-erc-o-algo-mas-como-decodificar-el-diagnostico/48861
Disallow: /programs/cme/conjunto-de-herramientas-para-el-tratamiento-del-pa-erc/48862
Disallow: /programs/cme/como-elevar-la-atencion-medica-del-pa-erc-nueva-frontera/48863
Disallow: /programs/cme/el-pa-erc-se-oculta-en-su-centro-de-dialisis/48864
Disallow: /programs/cme/contextos-de-opioides-kappa-datos-de-la-vida-real/48865
Disallow: /programs/cme/como-mejorar-el-sueno-y-la-salud-mental-en-pacientes-con-pa-erc/48866
Disallow: /programs/cme/the-patient-clinician-connection-in-managing-ckd-ap/48867
Disallow: /programs/cme/des-donnees-aux-debats-perspectives-mondiales-sur-la-prise-en-charge-du-csm-hrher2/51023
Disallow: /programs/cme/besoins-non-satisfaits-avec-lhormonotherapie-repenser-la-feuille-de-route-du-traitement-du-csm-hrher2/51024
Disallow: /programs/cme/analyse-des-criteres-de-reference-donnees-pivots-sur-les-inhibiteurs-des-cdk46-de-premiere-ligne/51025
Disallow: /programs/cme/securite-des-inhibiteurs-des-cdk46-anticipation-prevention-et-gestion-des-evenements-indesirables/51026
Disallow: /programs/cme/au-dela-du-fulvestrant-les-serd-oraux-redefinissent-le-ciblage-des-recepteurs-hormonaux/51027
Disallow: /programs/cme/lavenir-des-serd-oraux-strategies-de-combinaison/51028
Disallow: /programs/cme/doublet-ou-triplet-debats-autour-dun-cas-sur-les-choix-de-premiere-ligne-pour-un-csm-hrher2/51029
Disallow: /programs/cme/a-la-croisee-des-chemins-debat-autour-dun-cas-sur-la-selection-des-serd/51030
Disallow: /programs/cme/gros-plan-sur-leurope-adapter-les-donnees-probantes/51031
Disallow: /programs/cme/gros-plan-sur-lamerique-latine-combler-les-lacunes/51032
Disallow: /programs/cme/gros-plan-sur-lasie-pacifique-la-pratique-au-dela-des-frontieres/51033
Disallow: /programs/cme/von-daten-zur-diskussion-allgemeine-perspektiven-fur-die-behandlung-von-hrher2-mbc/51052
Disallow: /programs/cme/hrher2-mbc/51053
Disallow: /programs/cme/nicht-erfullte-bedurfnisse-in-der-endrokrinen-therapie-uberdenken-der-behandlungsstrategie-fur-hrher2-mbc/51054
Disallow: /programs/cme/aufschlusselung-der-benchmarks-entscheidende-daten-zu-cdk46-inhibitoren-in-der-erstlinientherapie/51055
Disallow: /programs/cme/sicherheit-von-cdk46-inhibitoren-antizipation-pravention-und-management-von-nebenwirkungen/51056
Disallow: /programs/cme/uber-fulvestrant-hinaus-orale-serds-definieren-er-targeting-neu/51057
Disallow: /programs/cme/die-zukunft-oraler-serds-kombinationsstrategien/51058
Disallow: /programs/cme/doppel-oder-dreifachtherapie-eine-fallbasierte-diskussion-zu-erstlinientherapien-fur-hrher2-mbc/51059
Disallow: /programs/cme/neubewertung-der-darreichungsformen-eine-fallbasierte-diskussion-zur-serd-auswahl/51060
Disallow: /programs/cme/europa-im-fokus-anpassung-der-evidenz/51061
Disallow: /programs/cme/lateinamerika-im-fokus-schlieen-der-versorgungslucke/51062
Disallow: /programs/cme/der-asien-pazifik-raum-im-fokus-grenzuberschreitende-praxis/51063
Disallow: /programs/cme/hrher2-mbc/51068
Disallow: /programs/cme/cdk46/51069
Disallow: /programs/cme/cdk46/51070
Disallow: /programs/cme/er-serd/51071
Disallow: /programs/cme/serd/51072
Disallow: /programs/cme/hrher2-mbc/51073
Disallow: /programs/cme/serd/51074
Disallow: /programs/cme/HRHER2mBC/51075
Disallow: /programs/cme/HRHER2mBC/51076
Disallow: /programs/cme/HRHER2mBC/51077
Disallow: /programs/cme/dos-dados-ao-debate-perspetivas-globais-sobre-o-tratamento-do-cancro-da-mama-metastatico-hrher2/51493
Disallow: /programs/cme/necessidades-nao-atendidas-na-terapia-endocrina-repensando-o-roteiro-de-tratamento-do-cmm-hrher2/51494
Disallow: /programs/cme/analisar-os-parametros-de-referencia-dados-fundamentais-sobre-os-inibidores-cdk46-de-primeira-linha/51495
Disallow: /programs/cme/seguranca-dos-inibidores-cdk46-antecipacao-prevencao-e-gestao-de-eventos-adversos/51496
Disallow: /programs/cme/alem-do-fulvestrant-serd-orais-redefinindo-o-alvo-er/51497
Disallow: /programs/cme/o-futuro-dos-serd-orais-estrategias-combinadas/51498
Disallow: /programs/cme/dupla-ou-tripla-um-debate-baseado-em-casos-sobre-opcoes-de-primeira-linha-para-cmm-hrher2/51499
Disallow: /programs/cme/rotas-reconsideradas-um-debate-baseado-em-casos-na-selecao-serd/51500
Disallow: /programs/cme/em-destaque-na-europa-adaptando-as-evidencias/51501
Disallow: /programs/cme/destaque-para-a-america-latina-fechar-a-lacuna/51502
Disallow: /programs/cme/destaque-para-a-asia-pacifico-pratica-alem-das-fronteiras/51503
Disallow: /programs/cme/de-los-datos-al-debate-perspectivas-globales-sobre-la-atencion-del-cmm-hrher2/54097
Disallow: /programs/cme/necesidades-insatisfechas-en-el-tratamiento-endocrino-reformulando-la-hoja-de-ruta-del-tratamiento-del-cmm-hrher2/54106
Disallow: /programs/cme/desglose-de-los-puntos-de-referencia-datos-fundamentales-sobre-inhibidores-de-cdk46-de-primera-linea/54107
Disallow: /programs/cme/seguridad-de-inhibidores-de-cdk46-anticipacion-prevencion-y-control-de-eventos-adversos/54108
Disallow: /programs/cme/mas-alla-del-fulvestrant-los-serd-orales-redefinen-el-objetivo-de-los-re/54109
Disallow: /programs/cme/el-futuro-de-los-serd-orales-estrategias-de-combinacion/54110
Disallow: /programs/cme/tratamiento-doble-o-triple-un-debate-basado-en-casos-sobre-las-opciones-de-primera-linea-para-el-cmm-hrher2/54111
Disallow: /programs/cme/reconsideracion-de-las-rutas-un-debate-basado-en-casos-sobre-la-seleccion-de-serd/54112
Disallow: /programs/cme/enfoque-en-europa-adaptacion-de-la-evidencia/54113
Disallow: /programs/cme/enfoque-en-latinoamerica-cerrando-la-brecha/54114
Disallow: /programs/cme/enfoque-en-asia-pacifico-practicas-mas-alla-de-las-fronteras/54115
Disallow: /programs/cme/hrher2-mbc/54163
Disallow: /programs/cme/hrher2-mbc/54164
Disallow: /programs/cme/cdk46/54165
Disallow: /programs/cme/cdk46/54166
Disallow: /programs/cme/serd-er/54167
Disallow: /programs/cme/serd/54168
Disallow: /programs/cme/hrher2-mbc/54169
Disallow: /programs/cme/serd/54170
Disallow: /programs/cme/ESMO/54171
Disallow: /programs/cme/ESMO/54172
Disallow: /programs/cme/ESMOHRHER2mBC/54173
Disallow: /live-events/qa-in-person-live-event-parent-2-child-2/56552
Disallow: /programs/advancing-care-in-cardiovascular-kidney-metabolic-ckm-syndrome
Sitemap: https://pace-cme.org/sitemap.xml